Estrella Immunopharma receives Nasdaq bid price deficiency notice; faces potential delisting

Estrella Immunopharma, Inc.

Nasdaq notified Estrella that common stock failed to maintain $1.00 minimum bid for 30 consecutive days through April 28, 2025.
Company has 180-day compliance period (until October 27, 2025) to regain compliance with Bid Price Rule.
If not compliant by October 27, may seek additional 180-day period if it meets other listing standards.
No immediate effect on listing; common stock and warrants continue trading on Nasdaq under ESLA and ESLAW.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.